| |
Research Description:
My laboratory is involved in preclinical and clinical pharmacology studies of investigational and non-investigational antitumor drugs. Funded studies involve murine metabolism and disposition studies and Phase I and II clinical trials of individual agents and novel combinations of cytotoxic and non-cytotoxic compounds. We are also actively engaged in a number of studies of drugs given locally or regionally, e.g. intraperitoneal, intrathecal, intrapleural, and intravesical. Major classes of drugs under study include taxanes, anthracyclines, tyrosine kinase inhibitors, PI3 kinase inhibitors, and Heat Shock Protein 90-interactive agents. An emphasis is placed on relating pharmacokinetics and pharmacodynamics of the agents under study and developing novel limited sampling strategies and innovative non-invasive means of assessing drug concentration and drug effect.
Education:
B.A., Johns Hopkins University, Baltimore, MD 1969
M.D., Johns Hopkins University, Baltimore, MD 1973
Medical Internship and Residency, The Johns Hopkins Hospital, Baltimore, MD 1973-1975
Clinical Associate, Laboratory of Clinical Biochemistry, NCI, Baltimore 1975-1978
Important Publications:
- Eiseman JL, J Guo, RK Ramanathan, CP Belani, DB Solit, HI Scher, SP Ivy, EG Zuhowski and MJ Egorin. Evaluation of insulin-like growth factor binding protein 2 (IGBP-2) and Her-2 extracellular domain (Her-2 ECD) as biomarkers for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients with advanced solid tumors. Clinical Cancer Research, in press, 2007
- Beumer JH, JL Eiseman, RA Parise, E Joseph, JL Holleran, JM Covey and MJ Egorin. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor, 5-Fluoro-2’-deoxycytidine (FdCyd), in mice. Clinical Cancer Research 12:7483-7491, 2006
- Lichtman SM, D Hollis, AA Miller, GL Rosner, CA Rhoades, EP Lester, F Millard, J Byrd, SA Cullinan, DM Rosen, RA Parise, MJ Ratain and MJ Egorin. Prospective evaluation of the Relationships of patient age and paclitaxel clinical pharmacology: CALGB 9762. Journal of Clinical Oncology 24:1846-1851, 2006
- Parise RA, JL Holleran, S Ramalingam and MJ Egorin. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, Vorinostat (suberoylanilide hydroxamic acid, SAHA), and its metabolites in human serum. Journal of Chromatography B 840:108-115, 2006
- Egorin MJ. The effects of organ dysfunction on drug dosing. Clin Adv Hematol Oncol 4:116-118, 2006
|
